Published in Mediators Inflamm on January 01, 1994
Diagnosis and classification of multiple sclerosis. Br Med Bull (1977) 4.68
Natural killer cells: their roles in defenses against disease. Science (1981) 4.59
Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet (1987) 3.79
Capacity of human large granular lymphocytes (LGL) to produce multiple lymphokines: interleukin 2, interferon, and colony stimulating factor. J Immunol (1983) 1.84
Interferon activation of "pre-spontaneous killer" (pre-SK) cells and alteration in kinetics of lysis of both "pre-SK" and active SK cells. J Immunol (1980) 1.75
Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro. Studies of patients with multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis. Clin Exp Immunol (1982) 1.14
Interferon in the serum and cerebrospinal fluid in patients with multiple sclerosis and other neurological disorders. Acta Neurol Scand (1976) 1.14
A whole-blood technique for testing production of human interferon by leukocytes. J Immunol Methods (1982) 1.03
Induction of an inhibitor of interferon action in a mouse lymphokine preparation. Infect Immun (1979) 1.03
The role of natural killer cells in human disease. Clin Immunol Immunopathol (1989) 0.96
Natural killer cell activity in patients with multiple sclerosis: interferon and plasmapheresis. Immunobiology (1982) 0.88
Evaluation of cell damage in immune reactions by release of radioactivity from 3 H-uridine labeled cells. Gan (1971) 0.87
Non-specific mechanisms of inflammation and tissue damage in MS. Res Immunol (1989) 0.86
Intermittent interferonemia and interferon responses in multiple sclerosis. Clin Immunol Immunopathol (1991) 0.85
Analysis of natural killer cells in patients with idiopathic autoimmune hemolytic anemia. Vox Sang (1989) 0.83
The beneficial effects of alpha IFN in CGL are probably not mediated by NK cells. Br J Haematol (1989) 0.81
Natural cytotoxic activity in multiple sclerosis patients: defects in IL-2/interferon gamma-regulatory circuit. Clin Exp Immunol (1986) 0.81
[Cryomethod of concentrating interferon (author's transl)]. Vopr Virusol (1976) 0.78
Alpha-interferon in myelodysplasia; clinical observations and effects on NK cells. Leuk Res (1988) 0.78
[Leukocytic interferon, an index of body reactivity normally and in pathology]. Vestn Akad Med Nauk SSSR (1979) 0.78
[Interferon-producing and cytotoxic activity of natural killer cells in multiple sclerosis patients]. Zh Nevropatol Psikhiatr Im S S Korsakova (1987) 0.78
[The role of adherent cells in supporting natural cytotoxicity reactions]. Biull Eksp Biol Med (1989) 0.77
[Evaluation of the interferon status of human subjects by whole-blood specimens]. Vopr Virusol (1989) 0.77
Systemic interferon therapy of multiple sclerosis: the pros. Neurology (1988) 0.77
Morphogenesis of Venezuelan equine encephalomyelitis virus. J Virol (1969) 1.06
Influence of PPLO on production of interferon in virus-infected cells. Virology (1965) 0.97
Architecture of Venezuelan equine encephalomyelitis virus. Virology (1965) 0.96
Isolation of oncornaviruses from continuous human cell cultures. Intervirology (1973) 0.86
Ribonucleic acids synthesized in Venezuelan equine encephalomyelitis virus-infected cells. Virology (1969) 0.86
Relationship between group A arbovirus reproduction and cytochemical changes in infected cells. Acta Virol (1968) 0.84
B-type oncornaviruses isolated from continuous human cancer cell lines. Arch Gesamte Virusforsch (1973) 0.83
Enhancement of the immune response by a catabolic product of normal rabbit IgG. Effect of F(ab')2-like fragment. Immunology (1976) 0.83
Formation of infectious arbovirus ribonucleoprotein in subcellular structures. Nature (1970) 0.80
Interferon induction by, and antiviral effect of poly (rI)--poly (rC) in experimental viral infection. Acta Virol (1973) 0.79
Photodynamic and fluorochromic properties of the antibiotic actinomycin D. J Cell Physiol (1965) 0.79
Further studies of the adjuvant properties of homologous IgG split products: mode of action of F(ab')2 and related fragments. Immunology (1978) 0.76
Naturally occurring antiglobulin factors in virus neutralization: homoreactant as a factor enhancing neutralization of the infectious complex of poliovirus with the Fab' antibody fragment. Infect Immun (1976) 0.75
Formation of ribonucleoprotein particles by interaction of infectious viral RNA with cytoplasmic cell fractions. Arch Gesamte Virusforsch (1971) 0.75
Characteristics of Venezuelan equine encephalomyelitis virus ribonucleoprotein. Arch Gesamte Virusforsch (1971) 0.75
The effect of combination of different inducers on the refractory state in interferon production. Acta Virol (1976) 0.75
[Interactions of interferon with other immunomodulators in the regulation of human natural killer cell activity]. Biull Eksp Biol Med (1992) 0.75
On the synthesis of viral ribonucleic acids and ribonucleoproteins in the submitochondrial system completely free of interfering cytoplasmic contaminations. Mol Cell Biochem (1976) 0.75
[Natural killer activity in respiratory papillomatosis and its changes after interferon treatment]. Vopr Virusol (1992) 0.75
A leukovirus isolated from cells obtained from leukemic calf lymph nodes. Br Vet J (1975) 0.75
2 cell-free systems for the assay of virus-specific polymerase. Experientia (1970) 0.75
[Regulation of the activity of human natural killer cells by autologous interferon]. Biull Eksp Biol Med (1994) 0.75
[Fibronectin as a compensation factor in the natural cytotoxicity system in interferon-dependent immunodeficiency]. Biull Eksp Biol Med (1994) 0.75
[The effect of exogenous interferon on the in vitro production of alpha- and gamma-interferon by the lymphocytes of patients with respiratory papillomatosis]. Vopr Virusol (1992) 0.75
Oncornaviruses type D and their possible role in neoplastic processes. Prog Med Virol (1977) 0.75
The role of cytokine mRNAs in cell sensitivity to alpha-interferon. Dokl Biol Sci (2002) 0.75
[The natural cytotoxicity system in patients with multiple sclerosis: clinico-immunological parallels]. Zh Nevropatol Psikhiatr Im S S Korsakova (1989) 0.75
[Circulating serum interferon and its effect on human natural killer cell activity]. Biull Eksp Biol Med (1994) 0.75
Properties of virions and ribonucleoproteins of Venezuelan equine encephalomyelitis virus. Acta Virol (1977) 0.75
[The interferon status and circulating immunoglobulins during the interferon therapy of respiratory papillomatosis in children]. Vopr Virusol (1992) 0.75
[Age-related characteristics of the natural cytotoxicity system in patients with multiple sclerosis and their possible relation to the pathogenesis of the disease]. Zh Nevropatol Psikhiatr Im S S Korsakova (1991) 0.75
[Effectiveness of human leukocytic interferon in children with papillomatosis of the larynx, trachea and bronchi]. Vestn Otorinolaringol (1992) 0.75
Comparative immunological studies of IgG and naturally occurring anti-globulin factors to pepsin and papain fragments of homologous IgG. Clin Immunol Immunopathol (1976) 0.75
Proteins of Venezuelan equine encephalomyelitis virions. Experientia (1971) 0.75
The dynamics of development of cell resistance to viruses induced by synthetic polynucleotides. Acta Virol (1976) 0.75
Properties of interferons produced by different cell populations. Acta Microbiol Hung (1988) 0.75
[Antibodies against alpha-2 and gamma-interferons affect the course of juvenile respiratory papillomatosis in children treated with alpha-2 interferon preparations]. Vestn Otorinolaringol (1997) 0.75